DexCom, Inc. - Common Stock (DXCM)

There should be plenty of long-term upside for these stocks for investors willing to ride out the storm.

Over the last six months, DexCom’s shares have sunk to $80.25, producing a disappointing 9.9% loss - a stark contrast to the S&P 500’s 5.8% gain. This may have investors wondering how to approach the situation.

Medical device company DexCom (NASDAQ:DXCM) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 15.2% year on year to $1.16 billion. The company expects the full year’s revenue to be around $4.61 billion, close to analysts’ estimates. Its non-GAAP profit of $0.48 per share was 7.8% above analysts’ consensus estimates.

DexCom (DXCM) offers strong growth, fair valuation, and solid profitability, making it a top pick for investors seeking affordable growth in the medical device sector.

A post-earnings surge in Meta Platforms Inc. (NASDAQ:META) and Microsoft Corp.

Get insights into the S&P500 index performance on Monday. Explore the top gainers and losers within the S&P500 index in today's session.

Curious about the S&P500 stocks that are in motion on Monday? Join us as we explore the top movers within the S&P500 index during today's session.

Wondering what's happening in today's session regarding gap up and gap down stocks? Explore the S&P500 index on Monday to uncover the stocks that are gapping in the S&P500 index.

Stay informed about the performance of the S&P500 index in the middle of the day on Thursday. Uncover the top gainers and losers in today's session for valuable insights.

Looking for opportunities in today's market? Check out the S&P500 gap up and gap down stocks on Thursday and stay ahead of the market trends.

Medical device company DexCom (NASDAQ:DXCM) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 15.2% year on year to $1.16 billion. The company expects the full year’s revenue to be around $4.61 billion, close to analysts’ estimates. Its non-GAAP profit of $0.48 per share was 7.8% above analysts’ consensus estimates.

After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable S&P500 performers among the top gainers and losers.

Dexcom stock fell late Wednesday after it reported Q2 earnings that topped expectations and named a new chief executive officer.

Medical device company DexCom (NASDAQ:DXCM) will be reporting results this Wednesday after market hours. Here’s what to look for.

A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south. While some investors embrace risk, mistakes can be costly for those who aren’t prepared.

DexCom (DXCM) is a top growth stock with strong fundamentals, solid profitability, and bullish technical breakout signals, making it a compelling investment opportunity.

An update on Sana Biotechnology.

DEXCOM INC (NASDAQ:DXCM) shows a strong technical setup with positive trends, consolidation, and institutional interest, making it a breakout candidate for traders.